Moderna stock climbs

Moderna surged 5% to $152.83, extending a 137% one-month run fueled by Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk.

“49% reduction in recurrence risk”

BioNTech stock edges up

BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets are backing Moderna's specific asset rather than the broader platform.

Phase 3 interim analysis expected

Moderna guided to an interim analysis from its Phase 3 adjuvant melanoma trial in the second half of 2026, with management stating they are 'highly confident' the interim will be conducted this year.

“highly confident”

Merck partnership details

Merck is Moderna's partner on the individualized neoantigen program, which now spans nine Phase 2/3 trials across melanoma, non-small cell lung cancer, bladder and renal cell carcinoma.

BioNTech's medical officer statement

BioNTech's chief medical officer stated that 'in terms of biology and indication, we don't see any read through opportunities. Melanoma versus colorectal cancer, these are very different biologies and indications and responsiveness to immunotherapy'.

“in terms of biology and indication, we don't see any read through opportunities”

Novavax stock moves up

Novavax stock rose 2% to $9.5 as a vaccine-sector name in the group, not a participant in the messenger RNA cancer vaccine program.

Market reaction to data

The market is pricing Moderna's specific asset rather than the broader mRNA cancer vaccine platform, with BioNTech's muted move indicating the market is underwriting Moderna's program.

Next data window

The Madrid oncology congress in late October is the next scheduled opportunity for Moderna to release the underlying survival curves, subgroup detail and safety picture behind the headline number.

What to watch next

Investors should watch for whether Moderna issues its Phase 3 interim analysis before Madrid and whether management pairs it with accelerated-review language.